Onconetix, Inc. Current Income Tax Expense (Benefit)
Onconetix, Inc. (ONCO) reported Current Income Tax Expense (Benefit) of $56.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2025-11-13
- Onconetix, Inc. current income tax expense (benefit) for the quarter ending 2024-09-30 was $56.00K.
- Onconetix, Inc. current income tax expense (benefit) for the quarter ending 2024-06-30 was $51.00K.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month |
|---|---|---|---|
| 2024-09-30 | $56.00K 10-Q · filed 2025-11-13 | $107.00K derived: sum of 2 quarters · filed 2025-11-13 | $127.00K 10-Q · filed 2025-11-13 |
| 2024-06-30 | $51.00K 10-Q · filed 2025-08-14 | $71.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |